Compare · BIO vs LAB
BIO vs LAB
Side-by-side comparison of Bio-Rad Laboratories Inc. (BIO) and Standard BioTools Inc. (LAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIO and LAB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BIO is the larger of the two at $6.92B, about 19.0x LAB ($365.2M).
- Over the past year, BIO is up 8.4% and LAB is down 23.0% - BIO leads by 31.3 points.
- LAB has been more active in the news (7 items in the past 4 weeks vs 3 for BIO).
- BIO has more recent analyst coverage (11 ratings vs 5 for LAB).
- Company
- Bio-Rad Laboratories Inc.
- Standard BioTools Inc.
- Price
- $256.19-8.55%
- $0.93+0.80%
- Market cap
- $6.92B
- $365.2M
- 1M return
- -7.99%
- +1.00%
- 1Y return
- +8.38%
- -22.97%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1980
- 2011
- News (4w)
- 3
- 7
- Recent ratings
- 11
- 5
Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Latest BIO
- Bio-Rad Reports First-Quarter 2026 Financial Results
- Bio-Rad to Report First-Quarter 2026 Financial Results on Thursday, April 30, 2026
- Bio-Rad Labs downgraded by Citigroup with a new price target
- Bio-Rad Reports Fourth-Quarter and Full-Year 2025 Financial Results
- Bio-Rad to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 12, 2026
- Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 44th Annual Healthcare Conference
- Bio-Rad Reports Third-Quarter 2025 Financial Results
- Bio-Rad to Report Third Quarter 2025 Financial Results on Wednesday, October 29, 2025
- Bio-Rad Laboratories, Inc. Co-Founder and Director Emeritus Alice Schwartz Passes Away
- Bio-Rad's Management to Participate in Upcoming Investor Conferences
Latest LAB
- SEC Form DEFA14A filed by Standard BioTools Inc.
- SEC Form DEF 14A filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
- SEC Form 4 filed by Egholm Michael
- SEC Form 4 filed by Kim Hanjoon Alex
- SEC Form 4 filed by Mackay Sean
- SEC Form 10-K filed by Standard BioTools Inc.
- Director Casdin Eli was granted 52,991 shares, increasing direct ownership by 2% to 2,954,053 units (SEC Form 4)
- Director Cox Troy was granted 57,264 shares, increasing direct ownership by 18% to 376,586 units (SEC Form 4)